<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Vasopressors in Hypotension</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Todd A. Seigel, MD</div><div><strong>Updated:</strong> <!-- -->8/20/2013</div></div><div class="card__content"><h1 id="choosing-the-right-vasopressor-agent-in-hypotension">Choosing the Right Vasopressor Agent in Hypotension</h1>
<h2 id="table-of-vasopressor-effects-side-effects-and-prototypical-clinical-scenario">Table of Vasopressor Effects, Side Effects, and Prototypical Clinical Scenario</h2>
<p>Side effects of vasoactive medications are related both to the direct mechanism of action of the agent, as well as the compensatory mechanisms precipitated by them. Concerning side effects of inotropes include dysrhythmias and increased myocardial oxygen demand, whereas vasopressors can cause undesired limitations in blood flow to the gut and kidneys.</p>
<table>
<thead>
<tr>
<th><strong>Agent</strong></th>
<th align="center"><strong>Primary Receptor</strong></th>
<th><strong>Primary Impact</strong></th>
<th><strong>Potential Side Effect</strong></th>
<th><strong>Prototypical Clinical Scenario</strong></th>
</tr>
</thead>
<tbody><tr>
<td>Phenylephrine</td>
<td align="center">α<sub>1</sub></td>
<td>Increased SVR</td>
<td>Reflexive decreased HR</td>
<td>Neurogenic shock</td>
</tr>
<tr>
<td>Vasopressin</td>
<td align="center">V</td>
<td>Increased SVR</td>
<td>Decreased splanchnic flow</td>
<td>Adjunct for septic shock</td>
</tr>
<tr>
<td>Dobutamine</td>
<td align="center">β<sub>1</sub>, β<sub>2 </sub></td>
<td>Increased inotropy</td>
<td>Transient decreases in SVR (β<sub>2 </sub>agonsim)</td>
<td>Cardiogenic shock from late-stage heart failure</td>
</tr>
<tr>
<td>Dopamine (low-dose)</td>
<td align="center">D, β<sub>1</sub></td>
<td>Increased inotropy and heart rate</td>
<td>Tachydysrhythmias</td>
<td>Cardiogenic shock, particularly if bradycardic</td>
</tr>
<tr>
<td>Epinephrine</td>
<td align="center">α<sub>1</sub>, α<sub>2, </sub>β<sub>1</sub>, β<sub>2 </sub></td>
<td>Increased SVR and inotropy</td>
<td>Tachydysrhythmias and decreased splanchnic flow</td>
<td>Anaphylaxis</td>
</tr>
<tr>
<td>Norepinephrine</td>
<td align="center">α1, α2, β1&gt;&gt; β2</td>
<td>Increased SVR and inotropy</td>
<td>Decreased splanchnic and renal flow</td>
<td>Septic shock</td>
</tr>
<tr>
<td>Dopamine (high-dose)</td>
<td align="center">D, α1, β1&gt;&gt; β2</td>
<td>Increased SVR and inotropy</td>
<td>Tachydysrhythmias and decreased splanchnic/renal flow</td>
<td>Bradycardic cardiovascular collapse</td>
</tr>
</tbody></table>
<h2 id="references">References</h2>
<ul>
<li>Vasu TS, Cavallazzi R, Hirani A, Kaplan G, Leiby B, Marik PE. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med 2012;27:172-8. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/21436167">PubMed</a>]</li>
<li>Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370:676-84. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=17720019">PubMed</a>]</li>
<li>Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008;34:2226-34. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18654759">PubMed</a>]</li>
<li>Ellender TJ, Skinner JC. The use of vasopressors and inotropes in the emergency medical treatment of shock. Emerg Med Clin North Am 2008;26:759-86, ix. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/18655944">PubMed</a>]</li>
<li>De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 2012;40:725-30. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/22036860">PubMed</a>]</li>
</ul>
<p>Click here [<a href="https://www.aliem.com/2013/choosing-the-right-vasopressor-agent-in-hypotension/">Source</a>] for full ALiEM blog post</p>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"vasopressors-in-hypotension","title":"Vasopressors in Hypotension","authors":["Todd A. Seigel, MD"],"categories":[{"slug":"critical-care","name":"Critical Care"},{"slug":"cardiovascular","name":"Cardiovascular"}],"created":"2013/08/20","updated":null,"body":"\n# Choosing the Right Vasopressor Agent in Hypotension\n\n## Table of Vasopressor Effects, Side Effects, and Prototypical Clinical Scenario\n\nSide effects of vasoactive medications are related both to the direct mechanism of action of the agent, as well as the compensatory mechanisms precipitated by them. Concerning side effects of inotropes include dysrhythmias and increased myocardial oxygen demand, whereas vasopressors can cause undesired limitations in blood flow to the gut and kidneys.\n\n| **Agent**            |                     **Primary Receptor**                     | **Primary Impact**                | **Potential Side Effect**                             | **Prototypical Clinical Scenario**              |\n| -------------------- | :----------------------------------------------------------: | --------------------------------- | ----------------------------------------------------- | ----------------------------------------------- |\n| Phenylephrine        |                         α\u003csub\u003e1\u003c/sub\u003e                        | Increased SVR                     | Reflexive decreased HR                                | Neurogenic shock                                |\n| Vasopressin          |                               V                              | Increased SVR                     | Decreased splanchnic flow                             | Adjunct for septic shock                        |\n| Dobutamine           |                β\u003csub\u003e1\u003c/sub\u003e, β\u003csub\u003e2 \u003c/sub\u003e                 | Increased inotropy                | Transient decreases in SVR (β\u003csub\u003e2 \u003c/sub\u003eagonsim)    | Cardiogenic shock from late-stage heart failure |\n| Dopamine (low-dose)  |                       D, β\u003csub\u003e1\u003c/sub\u003e                       | Increased inotropy and heart rate | Tachydysrhythmias                                     | Cardiogenic shock, particularly if bradycardic  |\n| Epinephrine          | α\u003csub\u003e1\u003c/sub\u003e, α\u003csub\u003e2, \u003c/sub\u003eβ\u003csub\u003e1\u003c/sub\u003e, β\u003csub\u003e2 \u003c/sub\u003e  | Increased SVR and inotropy        | Tachydysrhythmias and decreased splanchnic flow       | Anaphylaxis                                     |\n| Norepinephrine       |                       α1, α2, β1\u003e\u003e β2                        | Increased SVR and inotropy        | Decreased splanchnic and renal flow                   | Septic shock                                    |\n| Dopamine (high-dose) |                        D, α1, β1\u003e\u003e β2                        | Increased SVR and inotropy        | Tachydysrhythmias and decreased splanchnic/renal flow | Bradycardic cardiovascular collapse             |\n\n## References\n\n- Vasu TS, Cavallazzi R, Hirani A, Kaplan G, Leiby B, Marik PE. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials. J Intensive Care Med 2012;27:172-8. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21436167)]\n- Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007;370:676-84. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/?term=17720019)]\n- Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008;34:2226-34. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18654759)]\n- Ellender TJ, Skinner JC. The use of vasopressors and inotropes in the emergency medical treatment of shock. Emerg Med Clin North Am 2008;26:759-86, ix. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18655944)]\n- De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 2012;40:725-30. [[PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22036860)]\n\nClick here [[Source](https://www.aliem.com/2013/choosing-the-right-vasopressor-agent-in-hypotension/)] for full ALiEM blog post\n"}}},"page":"/card","pathname":"/card","query":{"slug":"vasopressors-in-hypotension"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>